Meeting
2016 ASCO Annual Meeting
Hospitalizations and deaths within 60 days of fluoropyrimidine chemotherapy initiation among Medicare patients with colorectal cancer.
Authors
Gabriel Brooks
Dana-Farber Cancer Institute, Boston, MA
Gabriel Brooks , Angel Cronin , Deborah Schrag
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3603)
DOI
10.1200/JCO.2016.34.15_suppl.3603
Abstract #
3603
Poster Bd #
300
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real-world experience of an in-house dihydropyrimidine dehydrogenase (DPYD) genotype test to guide fluoropyrimidine (FP) dosing at a multisite cancer hospital.
First Author: Jai Narendra Patel
Poster
2021 ASCO Quality Care Symposium
Sustainability and clinical outcomes of routine screening for pathogenic DPYD gene variants prior to fluoropyrimidine (FP) chemotherapy for gastrointestinal (GI) cancer.
First Author: Gabriel A. Brooks
Poster
2021 ASCO Annual Meeting
Pre-therapeutic dihydropyridimidine dehydrogenase (DPD) deficiency screening: Impact on fluoropyrimidine dose reduction at the second chemotherapy cycle and on early severe toxicity.
First Author: Côme De Metz
Poster
2020 Gastrointestinal Cancers Symposium
Prospective DPYD testing and dose adjustment in colorectal cancer patients prior to fluoropyrimidine-based chemotherapy: Experience in a regional cancer center.
First Author: Janet Shirley Graham